Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Reports Increased Revenues, Income in Q1 for Standalone Operations

NEW YORK, June 10 (GenomeWeb News) - Stratagene yesterday reported increased revenues and earnings for its stand-alone operations for the first quarter of 2004. The results do not include those of Hycor Biomedical.

 

Stratagene was privately owned until June 2, when it merged with Hycor. The first quarter financial statement does include results from BioCrest Holdings "due to common control and management." Stratagene acquired the assets of BioCrest on June 2.

 

Revenues for the first quarter increased to $19.4 million, up from $16.9 million during the same quarter last year.

 

R&D expenses decreased to $2.5 million, from $2.8 million during the year-ago period.

 

Income climbed to $2.1 million, up from $1.3 million during the same quarter in 2003.

 

As of March 31, Stratagene had $3.1 million in cash and cash equivalents.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.